摘要
目的 观察重组人生长激素对原发性肾病综合征儿童矮小症的临床疗效和安全性。方法 将原发性肾病综合征儿童矮小症患儿分为对照组和试验组。对照组口服醋酸泼尼松片,初始剂量2 mg·kg^(-1)·d^(-1)、顿服,单日最大剂量不超过60 mg,足量给药持续时间6周后,每2周减少2.5 mg,直至维持剂量5~10 mg·d^(-1),持续给药12个月。试验组在对照组的基础上,每晚睡前0.5 d,通过皮下注射方式给予重组人生长激素0.15 U·kg^(-1),疗程为12个月。比较2组患者的身高、骨龄、身高标准差分数(HtSDS)和胰岛素样血清生长因子1(IGF-1)、胰岛素样生长因子结合蛋白3(IGFBP-3)水平,以及药物不良反应的发生情况。结果 对照组和试验组,每组各63例。治疗后试验组和对照组患儿的身高分别为(146.48±6.76)和(138.62±4.95)cm;HtSDS分别为-1.72±0.18和-1.97±0.20,IGF-1分别为(158.86±18.24)和(113.14±15.88) ng·mL^(-1),IGFBP-3分别为(5.21±0.83)和(3.13±0.71)μg·mL^(-1),在统计学上差异均有统计学意义(均P<0.05)。试验组与对照组的药物不良反应发生率为9.52%(6例/63例)和3.17%(2例/63例),在统计学上差异无统计学意义(P>0.05)。结论 重组人生长激素治疗原发性肾病综合征儿童矮小症的临床疗效确切,安全性高,有效促进生长发育。
Objective To observe the clinical efficacy and adverse drug reactions of recombinant human growth hormone on dwarfism in children with primary nephrotic syndrome.Methods Children with dwarfism in primary nephrotic syndrome were divided into control group and treatment group.Patients in control group were orally administered prednisone acetate tablets,with an initial dose of 2 mg·kg^(-1)·d^(-1),at once,no more than 60 mg in a single day,and after a duration of 6 weeks of full dosage,the dosage was reduced by 2.5 mg levery 2 weeks until the maintenance dose of 5-10 mg · d^(-1) was administered for 12 months.Patients in treatment group were injected subcutaneously with recombinant human growth hormone 0.15 U·kg^(-1) at 0.5 h before bedtime every night on the basis of control group for a period of 12months.The levels of height,bone age,standard deviation fraction of height(HtSDS),insulin-like serum growth factor 1(IGF-1),insulin-like growth factor binding protein 3(IGFBP-3),and the incidence of adverse drug reactions were compared between the two groups.Results There were 63 cases in control group and 63 cases in treatment group.The height of the children in treatment group and control group after treatment were(146.48±6.76) and(138.62±4.95) cm;the HtSDS values were-1.72±0.18 and-1.97±0.20;the IGF-1 values were(158.86±18.24) and(113.14±15.88) ng·mL^(-1);IGFBP-3 values were(5.21±0.83) and(3.13±0.71) μg·mL^(-1),the differences were all statistically significant(all P <0.05).The incidence of adverse drug reaction in treatment group and control group were 9.52%(6 cases/63 cases) and 3.17%(2 cases/63 cases),with no statistically significant difference(P> 0.05).Conclusion Recombinant human growth hormone has a definite clinical efficacy,high safety,and effective promotion of growth and development in the treatment of primary nephrotic syndrome in children with dwarfism.
作者
胡潇豪
蔡英健
陈永存
吴敏
陈郎湖
HU Xiao-hao;CAI Ying-jian;CHEN Yong-cun;WU Min;CHEN Lang-hu(Department of Pediatrics,The Second Afiliated Hospital of Fujian Medical University,Quanzhou 362000,Fujian Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2024年第4期515-518,共4页
The Chinese Journal of Clinical Pharmacology
关键词
醋酸泼尼松片
重组人生长激素
原发性肾病综合征
儿童矮小症
胰岛素样生长因子1
acetate prednisone tablet
recombinant human growth hormone
primary nephrotic syndrome
childhood dwarfism
insulin like growth factor 1
